Bookmark Kaumudi Online  Bookmark this site  Editor@Kaumudi  |  Marketing  Print Advt rates  |  Calendar 2018        Go!    
 
 
June 19, Tuesday 2018 5:33 PM       

       HEADLINES: Important info in box found near Jasna's house                                              Strong action against ADGP's daughter if her complaint is fake: Behera                                              Dubai based NRI held for threatening to kill Pinarayi                                              Govt encouraging slave labour, says Chennithala                                              Students fall off school van, injured                                              Minister hospitalised on day seven of strike                                              Four Assam rifles jawans killed in Nagaland                                              Delhi HC asks who authorised Kejriwal's sit-in at LG's office                                              Three killed, 100 injured in Japan earthquake                                              Iran's president to visit Switzerland, Austria amid nuclear deal row                                              Messi regrets missing penalty against Iceland                                              Kaumudi Facebook
       SCI&TECH Next Article: Astronomers reveal secrets of most distant supernova ever detected  
       Liver cancer: New method identifies splicing biomarkers
 
         Posted on :17:31:17 Mar 3, 2018
   
A A
       Last edited on:17:31:17 Mar 3, 2018
         Tags: Liver cancer, splicing biomarkers
 

WASHINGTON DC: Turns out, a new method has identified splicing biomarkers for liver cancer.

According to a Cold Spring Harbor Laboratory-study, researchers have developed a method for identifying splicing-based biomarkers for the most common form of liver cancer, hepatocellular carcinoma (HCC).

The researchers, led by Professor Adrian Krainer, believed the method will be useful in other cancer types as well. Since, liver cancer is particularly diverse, genetically, and prone to relapse, identifying biomarkers that can predict disease progression is a critical goal in the fight against it.

"This study underscores the potential for learning how RNA splicing variants can contribute to cancer and points to these variants as potential biomarkers for cancer progression," Krainer said.

Splicing refers to a process in which an RNA message copied from information encoded in a gene is edited before it is able to serve as a blueprint for the manufacture of a specific protein.

A gene can give rise to multiple RNA messages, each resulting in a different protein variant, or "isoform." Many diseases have been associated with errors or variations in the way that RNA is spliced.

Errors or variations in splicing can lead to non-functional proteins or proteins with distinct or aberrant functions.

Recent studies have identified splicing irregularities in liver cancer cells. Led by researcher Kuan-Ting Lin, Krainer's team developed a method that comprehensively analyzes all RNA messages made from a given gene.

The team tested their splicing-variant detection method in HCC, by analysing RNA messages in HCC cells sampled from hundreds of patients.

They found that particular splicing isoforms of the gene AFMID correlated with very poor patient survival. These variants lead cells to manufacture truncated versions of the AFMID protein.

These unusual versions of the protein are associated with adult liver cancer cells with mutations in tumour-suppressor genes called TP53 and ARID1A.

These mutations, the researchers hypothesised, are associated with low levels of a molecule called NAD+ that is involved in repairing damaged DNA.

Restoring missing portions, called exons, to AFMID's normal RNA message, they proposed, might raise NAD+ to normal levels, avoiding mutations in TP53 and ARID1A.

The team hopes to use small molecules called ASOs (antisense oligonucleotides) that can bind to RNA, to change the way AFMID's RNA messages are spliced.

Krainer's team previously used this technique to correct errors in the splicing of the gene SMN2 as a way to treat spinal muscular atrophy (SMA).

Fixing AFMID splicing could lead to enhanced production of NAD+ and an increase in DNA repair. "If we can do this, AFMID splicing can become a therapeutic target and the source of a new drug for liver cancer," Lin said.

The study is published in the journal Genome Research.

A A
       SCI&TECH
Next Article: Astronomers reveal secrets of most distant supernova ever detected
 
 
SCI&TECH HEADLINES
Spironolactone can help prevent acne: Study  
Older Amazonian forests help regulate global climate  
Goal conflict linked to depressive symptoms  
A new world: Top 10 new species for 2018  
Beat the risk of frailty with healthy heart  
Twitter to hide trolls that hurl abuse: Twitter CEO  
Fortnite is finally coming to Android  
This test could detect signs of pancreatic cancer  
Aliens exist but may be in parallel Universe: Study  
This is your heart on nitric oxide  
Is your kid's heart clock ticking right?  
Do at-risk adolescents show depressive symptoms on social media?  
NASA launches Insight spacecraft to Mars for deepest dig yet  
Daily intake of this drug can cause certain cancers in men  
A new weapon against epilepsy  
Hail stone weighing three kg sign of climate change: Expert  
PMSing? Could be because of alcohol!  
Social media firms given a week to better protect kids  
The stronger you are, the healthier your brain is  
NASA may soon identify 2,400 alien planets  
What triggers depression among adults?  
Turn your hobbies into part-time job opportunities with these apps  
Apple launches special RED Edition for iPhone 8, 8 Plus  
Humanity‚Äôs first flight to Sun to launch in July: NASA  
This World Health Day, let's focus on eye health  
 
Do you think electric bus will be a success in Kerala?
Yes
 
No
 
No opinion
 
 
 
Home Kerala India World Business Sports Sci&Tech Education Automobile CityNews Movies Environment Letters 
© Copyright keralakaumudi Online 2011  |  Reproduction in whole or in part without written permission is prohibited.
Head Office Address: Kaumudi Buildings, Pettah P.O, Trivandrum - 695024, India.
Online queries talk to Deepu Sasidharan, + 91 98472 38959 or Email deepu[at]kaumudi.com
Customer Service -Advertisement Disclaimer Statement   |  Copyright Policy